CT/NG 測試市場 - 按產品類型、測試類型、技術、最終用途和預測，2024 年至 2032 年

CT/NG Testing Market - By Product Type, By Test Type, By Technology, By End-use & Forecast, 2024 - 2032

出版日期: 2024年05月07日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

「由於全球沙眼衣原體(CT) 感染盛行率不斷上升，預計2024 年至2032 年CT/NG 檢測市場規模的複合年成長率將達到7.1%。根據CDC 數據，2022 年報告的沙眼衣原體感染病例總數為1,649,716 例CT 是全球最常見的細菌性傳播感染之一，性行為改變、意識不足和醫療保健障礙等因素導致發病率上升，因為醫療保健系統優先考慮早期發現和治療以減輕傳播。的發展，對有效診斷解決方案的需求持續上升。

擴大採用基於聚合酶鏈反應 (PCR) 的檢測方法是主要的市場趨勢。 PCR 技術透過擴增遺傳物質，在檢測沙眼衣原體 (CT) 和淋病奈瑟菌 (NG) 感染方面具有高靈敏度和特異性。這種方法因其識別低水平感染的準確性而受到青睞，推動其在臨床診斷中的廣泛應用。隨著醫療保健提供者優先考慮精確和快速的檢測解決方案，基於 PCR 的檢測方法繼續受到關注，為市場成長做出了重大貢獻。

CT/NG 測試產業根據產品、測試類型、技術、最終用途和地區進行分類。

到 2032 年，儀器/分析儀領域將快速成長，因為它們為醫療保健專業人員提供了準確診斷的可靠工具。有一系列產品，包括核酸擴增測試（NAAT）、快速診斷測試（RDT）和分子診斷儀器。這些儀器旨在檢測 CT 和 NG 細菌的特定遺傳物質，從而能夠及早、準確地識別感染。製造商正在專注於開發方便用戶使用的設備，這些設備整合了自動化功能，並為醫療保健提供者提供具有成本效益的解決方案。

到 2032 年，聚合酶鏈反應 (PCR) 領域將以相當快的速度成長，因為它在檢測細菌 DNA 方面提供了高靈敏度和特異性。基於 PCR 的檢測方法因其能夠擴增微量遺傳物質而被廣泛採用，使其適用於低水平感染。隨著多重 PCR 等技術的進步，該技術不斷發展，可以在單一樣本中同時檢測多種病原體。基於 PCR 的測試因其可靠性和穩健的性能而在臨床環境中受到青睞，對市場成長軌跡做出了重大貢獻。

在有利的醫療政策、對性傳播感染預防的高度認知以及強大的醫療基礎設施的推動下，歐洲 CT/NG 檢測市場規模將在 2024 年和 2032 年穩步擴大。由於政府積極採取措施降低性傳染感染流行率，德國、法國和英國等國家擴大採用 CT/NG 檢測。對公共衛生和疾病監測的高度重視進一步支持了市場成長。此外，診斷技術的技術進步和主要參與者的存在有助於歐洲在 CT/NG 檢測市場的領導地位。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories
Becton, Dickinson and Company
binx health, inc.
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Cepheid
ELITech Group
Genetic Signatures
Hologic, Inc.
Meridian Bioscience
Qiagen
Roche
Seegene, Inc.
Thermo Fisher Scientific, Inc.
VIRCELL S.L.

簡介目錄

Product Code: 9397

"The CT/NG Testing Market size is anticipated to infer 7.1% CAGR during 2024-2032, driven by the escalating prevalence of chlamydia trachomatis (CT) infections worldwide. According to CDC, in 2022, the reported cases of chlamydia trachomatis infection totaled 1,649,716. CT is one of the most common bacterial STIs globally, affecting millions annually. Factors such as changing sexual behaviors, inadequate awareness, and barriers to healthcare access contribute to the rising incidence rates. As healthcare systems prioritize early detection and treatment to mitigate the spread of CT, the demand for effective diagnostic solutions continues to rise.

The increasing adoption of Polymerase Chain Reaction (PCR)-based assays is a major market trend. PCR technology offers high sensitivity and specificity in detecting chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) infections by amplifying genetic material. This method is favored for its accuracy in identifying low-level infections, driving its widespread integration in clinical diagnostics. As healthcare providers prioritize precise and rapid testing solutions, PCR-based assays continue to gain traction, contributing significantly to market growth.

The CT/NG testing industry is classified based on product, test type, technology, end-use, and region.

The instruments/analyzers segment will grow rapidly through 2032, as they provide healthcare professionals with reliable tools for accurate diagnosis. There is a range of products including nucleic acid amplification tests (NAATs), rapid diagnostic tests (RDTs), and molecular diagnostic instruments. These instruments are designed to detect specific genetic material from CT and NG bacteria, enabling early and precise identification of infections. Manufacturers are focusing on developing user-friendly devices that integrate automation and provide cost-effective solutions to healthcare providers.

Polymerase Chain Reaction (PCR) segment will grow at a decent rate through 2032, as it offers high sensitivity and specificity in detecting bacterial DNA. PCR-based assays are widely adopted due to their ability to amplify minute amounts of genetic material, making them suitable for low-level infections. The technology continues to evolve with advancements such as multiplex PCR, which allows the simultaneous detection of multiple pathogens in a single sample. PCR-based tests are preferred in clinical settings for their reliability and robust performance, contributing significantly to the market growth trajectory.

Europe CT/NG testing market size will expand at a steady pace during 2024 and 2032, driven by favorable healthcare policies, high awareness levels regarding STI prevention, and robust healthcare infrastructure. Countries like Germany, France, and the UK are witnessing increasing adoption of CT/NG testing due to proactive government initiatives aimed at reducing STI prevalence. The strong emphasis on public health and disease surveillance further supports market growth. Additionally, technological advancements in diagnostic techniques and the presence of key players contribute to Europe's leadership position in the CT/NG testing market."

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of sexually transmitted infections (STIs)
  - 3.2.1.2 Growing awareness and screening programs
  - 3.2.1.3 Advancements in testing technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Social stigma and under-reporting
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Instruments/Analyzers

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Laboratory testing
6.3 Point-of-care (POC) testing

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Isothermal nucleic acid amplification technology
7.3 Polymerase chain reaction
7.4 Immunodiagnostics
7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & clinics
8.3 Diagnostic laboratories
8.4 Home care setting
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa